Vivanza Biosci.

how big is Vivanza Biosci.?

As of Jun 06, Vivanza Biosciences Ltd has a market capitalization of 10.00 Cr, with recent net sales of 7.42 Cr and a net profit of -0.67 Cr over the last four quarters. Shareholder's funds are 4.64 Cr, and total assets amount to 19.50 Cr as of Mar'24.

Market Cap: As of Jun 06, Vivanza Biosciences Ltd has a market capitalization of 10.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes data from Mar'25, Dec'24, Sep'24, and Jun'24, is 7.42 Cr. The sum of Net Profit for the same quarters is -0.67 Cr. This data is presented on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is also on a Consolidated basis for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 4.64 Cr, while Total Assets amount to 19.50 Cr.

What does Vivanza Biosci. do?

Vivanza Biosciences Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, focusing on providing quality pharmaceutical products globally. Established in 1982, it reported net sales of 0 Cr and a net profit of -1 Cr for the quarter ending March 2025.

Overview:<BR>Vivanza Biosciences Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company, focusing on providing global quality pharmaceutical products at competitive prices.<BR><BR>History:<BR>Vivanza Biosciences Ltd was established in March 1982 and was initially known as Ivee Injectaa Limited. It transitioned from a Private Limited Company to a Public Limited Company in May 1992. The company rebranded and came into existence as Vivanza Biosciences in April 2016. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 10 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 32 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 2.15 <BR>Return on Equity: -16.92% <BR>Price to Book: 2.43<BR><BR>Contact Details:<BR>Address: 403 Sarthik 2 Opp Rajpath Club, S G Highway Ahmedabad Gujarat : 380054 <BR>Tel: 91-07405699869 <BR>Website: http://www.vivanzabiosciences.com

Who are in the management team of Vivanza Biosci.?

As of March 2022, the management team of Vivanza Biosci includes Hemant Parikh (Director), Sunil Shah (Independent Director), Avinash G. Bhojwani (Company Secretary & Compliance Officer), Apeksha Vyas (Independent Director), and Jayendra Mehta (Managing Director). Avinash G. Bhojwani is the only member receiving remuneration, amounting to Rs. 4.57 lacs.

As of March 2022, the management team of Vivanza Biosci includes the following individuals:<BR><BR>1. Hemant Parikh - Director<BR>2. Sunil Shah - Independent Director<BR>3. Avinash G. Bhojwani - Company Secretary & Compliance Officer<BR>4. Apeksha Vyas - Independent Director<BR>5. Jayendra Mehta - Managing Director<BR><BR>Avinash G. Bhojwani is the only member of the management team receiving remuneration, which is Rs. 4.57 lacs.

Has Vivanza Biosci. declared dividend?

No Dividend History Available

Who are the peers of the Vivanza Biosci.?

Vivanza Biosci.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Cian Healthcare, Beryl Drugs, Ortin Global, and Adline Chem Lab. While Sun Pharma, Cipla, and Dr Reddy's Labs show excellent management and growth, Vivanza Biosci. has below average performance with a 1-year return of -60.94%.

Peers: The peers of Vivanza Biosci. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Cian Healthcare, Beryl Drugs, Ortin Global, and Adline Chem Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest have below average management risk. Growth is excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is found at Vivanza Biosci., Divi's Lab., Torrent Pharma, Cian Healthcare, Beryl Drugs, Ortin Global, and Adline Chem Lab. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, whereas below average capital structure is present at Vivanza Biosci., Cian Healthcare, Beryl Drugs, Ortin Global, and Adline Chem Lab.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while Cian Healthcare has the lowest at -82.59%. Vivanza Biosci.'s 1-year return is -60.94%, which is significantly lower than Divi's Lab. and higher than Cian Healthcare. Additionally, the six-month return is negative for Vivanza Biosci., Cian Healthcare, Beryl Drugs, Ortin Global, and Adline Chem Lab.

Is Vivanza Biosci. overvalued or undervalued?

As of May 13, 2025, Vivanza Biosci. is considered risky and overvalued due to a negative PE ratio of -9.52, an EV to EBIT of -18.05, and a ROE of -16.92%, significantly underperforming compared to its peers, with a 59.33% decline in stock performance over the past year.

As of 13 May 2025, the valuation grade for Vivanza Biosci. has moved from attractive to risky, indicating a significant shift in the company's perceived value. The company is currently considered overvalued, given its negative PE ratio of -9.52 and an EV to EBIT of -18.05, which highlight underlying financial distress. Additionally, the ROE stands at -16.92%, further emphasizing the challenges faced by the company.<BR><BR>In comparison to its peers, Vivanza Biosci. lags significantly behind. For instance, Altius Telecom, rated very attractive, boasts a PE ratio of 52.97, while other peers like Embassy Office REIT and Inventurus Knowledge are categorized as very expensive with PE ratios of 23.06 and 56.63, respectively. The stark contrast in these ratios suggests that Vivanza Biosci. is not only underperforming but also carries a higher risk profile relative to its industry counterparts. Recent stock performance shows a decline of 59.33% over the past year, contrasting sharply with the Sensex's return of 7.65%, reinforcing the notion of overvaluation.

What is the technical trend for Vivanza Biosci.?

As of June 4, 2025, Vivanza Biosci's trend has shifted to mildly bearish, indicated by daily moving averages and weekly RSI, despite a mildly bullish weekly MACD, with overall indicators suggesting weakness and significant underperformance over the past year.

As of 4 June 2025, the technical trend for Vivanza Biosci has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly RSI showing bearish momentum. Although the weekly MACD is mildly bullish, the overall indicators, including the Bollinger Bands and KST on a monthly basis, suggest weakness. The Dow Theory indicates no clear trend in both weekly and monthly perspectives. The stock has underperformed significantly over the past year, further supporting the bearish outlook.

Who are the top shareholders of the Vivanza Biosci.?

The top shareholders of Vivanza Biosci are Parth Hemant Parikh with 19.77%, Ashoka Metcast Limited with 3.85%, and individual investors who collectively own 73.69%. There are no institutional investors or mutual funds involved.

The top shareholders of Vivanza Biosci include Parth Hemant Parikh, who holds the highest stake at 19.77%. The next significant public shareholder is Ashoka Metcast Limited, with a holding of 3.85%. Additionally, individual investors collectively hold a substantial 73.69% of the company's shares. There are no institutional investors or mutual funds involved in the shareholding.

How has been the historical performance of Vivanza Biosci.?

Vivanza Biosci. experienced significant financial declines, reporting net sales of 7.42 Cr in March 2025, down from 27.84 Cr in March 2024, resulting in a loss with a profit after tax of -0.67 Cr. The company faced negative cash flow and decreased total assets and liabilities during this period.

Answer:<BR>The historical performance of Vivanza Biosci. shows significant fluctuations in its financial metrics over the years, culminating in a loss in the most recent fiscal year.<BR><BR>Breakdown:<BR>Vivanza Biosci. reported net sales of 7.42 Cr in March 2025, a sharp decline from 27.84 Cr in March 2024 and 17.81 Cr in March 2023. The total operating income mirrored this trend, dropping to 7.42 Cr in March 2025 from 27.84 Cr in the previous year. Total expenditure also decreased to 7.79 Cr in March 2025 from 26.77 Cr in March 2024. Operating profit (PBDIT) turned negative at -0.31 Cr in March 2025, following a profit of 1.12 Cr in March 2024. Consequently, the profit before tax fell to -0.67 Cr in March 2025, down from 0.70 Cr in March 2024, leading to a profit after tax of -0.67 Cr compared to a profit of 0.55 Cr in the prior year. The company's total liabilities decreased to 16.45 Cr in March 2025 from 19.50 Cr in March 2024, while total assets also fell to 16.45 Cr from 19.50 Cr. Cash flow from operating activities was negative at -2.00 Cr in March 2025, contrasting with a positive cash flow of 2.00 Cr in March 2024. Overall, the financial performance indicates a challenging year for Vivanza Biosci., marked by declining revenues and profitability.

When is the next results date for Vivanza Biosciences Ltd?

The next results date for Vivanza Biosciences Ltd is 12 February 2026.

The next results date for Vivanza Biosciences Ltd is scheduled for 12 February 2026.

Are Vivanza Biosciences Ltd latest results good or bad?

Vivanza Biosciences Ltd's latest results show impressive year-on-year sales growth of 2916.67% to ₹45.25 crores, but a concerning 18.26% decline from the previous quarter and a low operating margin of 0.46%, raising questions about profitability and sustainability. Overall, the results are mixed, with significant concerns regarding financial health.

Vivanza Biosciences Ltd's latest results present a mixed picture. On one hand, the company reported an impressive year-on-year growth in net sales of 2916.67%, reaching ₹45.25 crores in Q3 FY26. This indicates a significant expansion in revenue compared to the previous year, when net sales were just ₹1.50 crores. However, this growth comes with a downside, as there was an 18.26% decline in sales compared to the previous quarter.<BR><BR>Profitability remains a critical concern. The net profit for Q3 FY26 was ₹0.20 crores, which, while showing a remarkable 400% increase year-on-year, reflects a substantial 64.29% decrease from the previous quarter. The operating margin is extremely low at 0.46%, indicating that the company is facing significant challenges in converting its revenue growth into meaningful profits.<BR><BR>Overall, while the explosive growth in sales is noteworthy, the substantial decline in profitability and the thin operating margins raise serious questions about the sustainability of this growth and the company's overall financial health. Thus, the results can be characterized as concerning, particularly regarding profitability and operational stability.

Should I buy, sell or hold Vivanza Biosciences Ltd?

Why is Vivanza Biosciences Ltd falling/rising?

As of 17-Mar, Vivanza Biosciences Ltd's stock price is Rs. 1.90, unchanged from the previous session, and has reached a new 52-week low. The stock has declined significantly over various time frames, indicating weak performance and challenges in long-term fundamentals.

As of 17-Mar, Vivanza Biosciences Ltd's stock price is currently at Rs. 1.90, showing no change from the previous trading session. The stock has recently hit a new 52-week low, indicating a downward trend. Over the past week, the stock has decreased by 5.94%, and it has also fallen by 9.52% over the past month. Year-to-date, the stock is down 13.64%, and it has underperformed significantly over the last three years with a staggering decline of 90.86%.<BR><BR>Despite some positive indicators, such as a 1,478.53% growth in net sales for the last nine months and a slight increase in delivery volume, the overall performance remains weak. The stock is trading below its moving averages across various time frames, which typically signals a bearish trend. Additionally, the company's long-term fundamentals are concerning, with a negative compound annual growth rate (CAGR) of operating profits over the last five years and a high debt-to-EBITDA ratio of 5.05 times, indicating challenges in servicing debt.<BR><BR>The stock's consistent underperformance against the benchmark, including a return of -9.95% in the last year compared to the Sensex's positive return of 2.56%, further supports the notion that Vivanza Biosciences Ltd is facing significant challenges, leading to its declining stock price.

Why is Vivanza Biosciences Ltd falling/rising?

As of 18-Mar, Vivanza Biosciences Ltd's stock price is Rs. 1.91, showing a minor increase but significant long-term decline, with a 90.81% drop over three years and a new 52-week low of Rs. 1.90. The company faces weak fundamentals, high debt levels, and underperformance against benchmarks.

As of 18-Mar, Vivanza Biosciences Ltd's stock price is currently at Rs. 1.91, reflecting a slight increase of Rs. 0.01 or 0.53%. Despite this minor rise, the stock has shown significant underperformance over various time periods. For instance, in the past week, the stock has decreased by 4.02%, and over the last month, it has fallen by 11.16%. Year-to-date, the decline stands at 13.18%, and over the past three years, the stock has plummeted by 90.81, indicating a consistent downward trend.<BR><BR>Today's performance highlights a new 52-week low of Rs. 1.90, which was hit earlier in the day, and the stock has underperformed its sector by 2.17%. Additionally, Vivanza Biosciences is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, further indicating weakness in its price momentum.<BR><BR>While there have been some positive financial results, such as an increase in net sales and profit after tax for the latest six months, the overall long-term fundamentals remain weak. The company has a high Debt to EBITDA ratio of 5.05 times, which suggests a low ability to service its debt. Furthermore, the stock has consistently underperformed against the benchmark indices, with a return of -7.73% over the last year and negative growth in operating profits over the past five years.<BR><BR>In summary, despite a slight uptick in the stock price today, Vivanza Biosciences Ltd is experiencing a broader trend of decline due to weak long-term fundamentals, significant underperformance against benchmarks, and a recent drop to a new 52-week low.

Why is Vivanza Biosciences Ltd falling/rising?

As of 19-Mar, Vivanza Biosciences Ltd's stock price is Rs. 1.91, unchanged from the previous session, and has recently reached a 52-week low of Rs. 1.90. The stock has shown significant declines over various time frames, underperforming against the benchmark Sensex, and is currently considered a strong sell due to weak financial metrics and bearish trends.

As of 19-Mar, Vivanza Biosciences Ltd's stock price is currently at Rs. 1.91, showing no change from the previous trading session. The stock has recently hit a new 52-week low of Rs. 1.90 today, indicating a downward trend. Over the past week, the stock has fallen by 3.54%, and over the past month, it has decreased by 7.73%. Year-to-date, the stock has dropped 13.18%, and in the last year, it has underperformed with a decline of 9.48%.<BR><BR>The company's performance has been significantly weaker compared to the benchmark Sensex, which has only fallen by 2.40% over the past week and 10.05% over the past month. Additionally, the stock has consistently underperformed against the benchmark over the last three years, with a staggering decline of 90.81% compared to the Sensex's 27.97% gain in the same period.<BR><BR>Investor participation has also decreased, as evidenced by a 44.04% drop in delivery volume compared to the five-day average. The stock is trading below all its moving averages, indicating a bearish trend. Furthermore, the company's long-term fundamentals are weak, highlighted by a -4.85% CAGR growth in operating profits over the last five years and a high Debt to EBITDA ratio of 5.05 times, suggesting a low ability to service debt.<BR><BR>While there are some positive factors, such as significant growth in net sales and a relatively attractive valuation compared to peers, the overall sentiment remains negative due to the company's consistent underperformance and weak financial metrics. Therefore, the stock is currently viewed as a strong sell.

Why is Vivanza Biosciences Ltd falling/rising?

As of 20-Mar, Vivanza Biosciences Ltd's stock price is stable at Rs 1.91, but it has experienced significant declines over various periods and is trading near its 52-week low. Despite some positive sales growth, the company shows weak financial metrics and consistent underperformance against benchmarks.

As of 20-Mar, Vivanza Biosciences Ltd is experiencing a stable stock price at Rs 1.91, with no change noted (0.00%). However, the stock has shown a significant decline over various periods, including a 1-week drop of 2.05%, a 1-month decrease of 9.05%, and a year-to-date decline of 13.18%. Over the past year, the stock has generated a return of -11.16%, which is notably worse than the benchmark Sensex, which has only declined by 2.38% during the same period.<BR><BR>The stock is currently trading close to its 52-week low, being just 0.52% away from Rs 1.90. Additionally, it is trading below all its moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Despite a rise in investor participation, with delivery volume increasing by 22.88% against the 5-day average, the overall performance remains weak.<BR><BR>Financially, the company has shown some positive results, such as a substantial growth in net sales of 1,478.53% over the first nine months, but this is overshadowed by a negative return on capital employed (ROCE) of -0.6 and a high debt-to-EBITDA ratio of 5.05 times, which indicates a low ability to service debt. Furthermore, the company has consistently underperformed against its benchmarks over the last three years, contributing to a weak long-term fundamental strength with a compound annual growth rate (CAGR) of -4.85% in operating profits over the last five years.<BR><BR>In summary, while there are some positive indicators, the overall trend shows that Vivanza Biosciences Ltd is falling due to consistent underperformance, weak financial metrics, and trading below key moving averages.

Which are the latest news on Vivanza Biosci.?